Insulet ROA 2007-2018 | PODD

Current and historical return on assets (ROA) values for Insulet (PODD) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Insulet ROA for the three months ending June 30, 2018 was -2.32%.
Insulet Annual ROA
2017 -3.29
2016 -5.96
2015 -22.39
2014 -16.13
2013 -15.62
2012 -26.19
2011 -20.71
2010 -39.15
2009 -41.85
2008 -87.56
2007 -40.95
2006 -62.92
2005 0.00
Insulet Quarterly ROA
Q2 2018 -0.20
Q1 2018 -0.79
Q4 2017 -0.84
Q3 2017 -0.45
Q2 2017 -1.69
Q1 2017 -2.24
Q4 2016 -2.00
Q3 2016 -0.67
Q2 2016 -1.65
Q1 2016 -4.20
Q4 2015 -5.78
Q3 2015 -6.14
Q2 2015 -5.75
Q1 2015 -3.42
Q4 2014 -0.62
Q3 2014 -3.60
Q2 2014 -8.95
Q1 2014 -2.13
Q4 2013 -0.87
Q3 2013 -7.35
Q2 2013 -3.68
Q1 2013 -3.80
Q4 2012 -5.15
Q3 2012 -6.11
Q2 2012 -7.11
Q1 2012 -6.85
Q4 2011 -6.48
Q3 2011 -6.29
Q2 2011 -3.57
Q1 2011 -6.61
Q4 2010 -13.35
Q3 2010 -8.08
Q2 2010 -8.46
Q1 2010 -9.11
Q4 2009 -8.99
Q3 2009 -14.45
Q2 2009 -20.38
Q1 2009 -16.39
Q4 2008 -26.98
Q3 2008 -16.01
Q2 2008 -15.55
Q1 2008 -17.06
Q4 2007 -11.98
Q3 2007 -10.06
Q2 2007 -8.50
Q1 2007 -24.24
Q4 2006 -19.04
Q3 2006 0.00
Q2 2006 0.00
Q1 2006 0.00
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $6.029B $0.464B
INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $132.148B 20.26
Abbott Laboratories (ABT) United States $121.136B 25.39
Stryker (SYK) United States $65.261B 25.22
Boston Scientific (BSX) United States $52.233B 27.17
Baxter (BAX) United States $41.336B 28.14
Zimmer Biomet Holdings (ZBH) United States $26.744B 17.18
ResMed (RMD) United States $16.242B 32.25
Smith & Nephew SNATS (SNN) United Kingdom $16.130B 0.00
Canopy Growth (CGC) Canada $11.376B 0.00
Perrigo (PRGO) Ireland $10.065B 14.28
Bio-Rad Laboratories (BIO) United States $8.905B 57.18
Hill-Rom Holdings (HRC) United States $6.065B 20.57
Haemonetics (HAE) United States $5.767B 52.63
ICU Medical (ICUI) United States $5.434B 36.82
Neogen (NEOG) United States $4.634B 73.73
GW Pharmaceuticals (GWPH) United Kingdom $4.582B 0.00
Agios Pharmaceuticals (AGIO) United States $4.266B 0.00
Hutchison China MediTech (HCM) China $3.798B 0.00
NuVasive (NUVA) United States $3.542B 33.60
National Vision Holdings (EYE) United States $3.271B 72.23
Quidel (QDEL) United States $2.532B 51.87
NxStage Medical (NXTM) United States $1.847B 0.00
Phibro Animal Health (PAHC) United States $1.708B 24.31
AtriCure (ATRC) United States $1.247B 0.00
Cardiovascular Systems (CSII) United States $1.233B 735.80
Omeros (OMER) United States $1.216B 0.00
VAREX IMAGING (VREX) United States $1.138B 18.60
Owens & Minor (OMI) United States $1.069B 11.44
PetIQ (PETQ) United States $1.069B 34.97
Eagle Pharmaceuticals (EGRX) United States $1.015B 29.95
Cerus (CERS) United States $0.985B 0.00
Surmodics (SRDX) United States $0.972B 117.42
MacroGenics (MGNX) United States $0.938B 0.00
OraSure Technologies (OSUR) United States $0.938B 61.32
TG Therapeutics (TGTX) United States $0.745B 0.00
Insys Therapeutics (INSY) United States $0.679B 0.00
LeMaitre Vascular (LMAT) United States $0.667B 32.00
Meridian Bioscience (VIVO) United States $0.642B 21.96
Lantheus Holdings (LNTH) United States $0.599B 18.63
Evolus (EOLS) United States $0.502B 0.00
NanoString Technologies (NSTG) United States $0.499B 0.00
Quanterix (QTRX) United States $0.427B 0.00
Cytosorbents (CTSO) United States $0.423B 0.00
Utah Medical Products (UTMD) United States $0.357B 22.97
Surface Oncology (SURF) United States $0.332B 0.00
BioLife Solutions (BLFS) United States $0.286B 0.00
Rockwell Medical (RMTI) United States $0.228B 0.00
Chimerix (CMRX) United States $0.191B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.172B 0.00
Fonar (FONR) United States $0.155B 7.73
Chembio Diagnostics (CEMI) United States $0.135B 0.00
Female Health (VERU) United States $0.099B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.085B 0.00
Trinity Biotech (TRIB) Ireland $0.082B 24.50
United-Guardian (UG) United States $0.076B 16.62
Neurotrope (NTRP) United States $0.066B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.059B 0.00
CAS Medical Systems (CASM) United States $0.057B 0.00
ImmuCell (ICCC) United States $0.049B 0.00
Capricor Therapeutics (CAPR) United States $0.033B 0.00
Valeritas Holdings (VLRX) United States $0.025B 0.00
Akers Biosciences Inc (AKER) United States $0.024B 0.00
Senestech (SNES) United States $0.019B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.009B 0.00